Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage 
Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
Company on track to initiate prophylactic study of PHVS416ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a...
Humacyte Announces Positive Long-Term Follow-Up Data from Phase 2 Vascular Access Trial
Five-year outcomes demonstrate HAV retained durability and structural integrity, potentially offering a safe and viable option for long-term hemodialysisLong-term explant...
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
WOBURN, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies...
Lowell Farms to Announce First Quarter Financial Results
Cannabis industry leader to hold conference call on May 5SALINAS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Lowell Farms (CSE:LOWL;...
Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)
SAVE 1 to evaluate ATI-2173 in combination with tenofovir (TDF) vs. TDF plus placebo SAVE 1 to include cohort of...
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury TroutGAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE)...
Virtual End-to-End Care in Workers’ Compensation to be Presented at RIMS
CorVel Session Looks at How the Pandemic Pushed Transformation of Care, Next StepsIRVINE, Calif., April 21, 2021 (GLOBE NEWSWIRE) --...
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission...
Top Scarless Robotic Thyroid Surgery Center Led By Surgeon Dr Hyun Suh Opened
North America’s leading Thyroid Surgery Center has established the Suh Scarless Thyroid Surgery Center in Tampa Florida, to provide the...
Cerevel Therapeutics Appoints Abraham N. Ceesay as President
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain...
Jushi Holdings Inc. Announces Certain Unaudited 2020 Fourth Quarter and Full Year 2020 Financial Results and Advises on Timing of Filing Annual Audited Financial Statements and Management’s Discussion and Analysis
--Fourth Quarter 2020 Revenue Increased 30% Sequentially to Revenue of $32.3 million; Gross Profit Increased 44% Sequentially to $17.6 million; Announces First...
Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum
CHATHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage...
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted...
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases
Khondrion announces first patients dosed in 6-month paediatric Phase II study of sonlicromanol for mitochondrial diseases Study will examine the...
Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum
BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing...
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Company Exceeds Target Enrollment in Less Than Six Weeks; Data Readout Expected by End of 2021LOS ALTOS, Calif., April 21,...
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development Newly Issued U.S. Patent Further Strengthens RMC-5552 IP Portfolio REDWOOD CITY, Calif.,...
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax
ULTRA-V Phase 2 trial has reached completion of patient enrollmentNEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:...
Silo Wellness Announces Five New Psychedelic Wellness Retreats in Jamaica
MONTEGO BAY, Jamaica, April 21, 2021 (GLOBE NEWSWIRE) -- Silo Wellness Inc. (“Silo Wellness” or “the Company”) (CSE: SILO) (FRA:3K70),...